Revenue

EBITDA

Earnings

Price per share at the end of the period divided by the last reported earnings

Free Cash Flow

Ardmore Shipping Corporation engages in the seaborne transportation of petroleum products and chemicals worldwide. As of February 15, 2022, the company operated a fleet of 25 double-hulled product and chemical tankers. It serves oil majors, oil companies, oil and chemical traders, chemical companies, and pooling service providers. The company was founded in 2010 and is based in Pembroke, Bermuda.

Ardmore Shipping Corporation

The significance of a company's longevity in the market

Years since IPO

Evaluation of recent trends and improvements in the company's revenue

Revenue Growth

Assessment of recent increases in earnings per share, indicating profitability

EPS Growth

Review of the company's ability to generate free cash flow over recent periods

FCF Growth

Analysis of Return on Equity, showing how effectively the company uses equity to generate profits

Examination of debt levels using Debt/Assets and Debt/EBITDA to ensure manageable leverage

Debt

- THE ELIMINATION HALF-LIFE OF ASC50 AFTER A SINGLE ORAL DOSE WAS 43, 89, 91, 87, 104, AND 85 HOURS FOR 10 MG, 30 MG, 100 MG, 200 MG, 400 MG, AND 600 MG, RESPECTIVELY, SUPPORTING ONCE - DAILY OR POTENTIALLY ONCE-WEEKLY ORAL DOSING. - ASC50 HAD STRONG TARGET ENGAGEMENT AFTER A SINGLE ORAL DOSE, INDICATED BY ELEVATED PLASMA INTERLEUKIN-17A (IL-17A) LEVELS, WHICH CONTINUED UNTIL DAY 7 FOR HIGHER DOSES OF ASC50.

ASCLETIS ANNOUNCES POSITIVE TOPLINE RESULTS FROM U.S. PHASE I STUDY OF ASC50, A POTENTIAL BEST-IN-CLASS ORAL SMALL MOLECULE IL-17 INHIBITOR

-DENIFANSTAT (ASC40) MET ALL PRIMARY, KEY SECONDARY AND SECONDARY EFFICACY ENDPOINTS (ITT ANALYSIS) AND SIGNIFICANTLY IMPROVED MODERATE-TO-SEVERE ACNE VULGARIS COMPARED WITH PLACEBO IN A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, MULTICENTER PHASE III CLINICAL TRIAL. HONG KONG , DEC. 10, 2025 /PRNEWSWIRE/ --ASCLETIS PHARMA INC. (HKEX: 1672, "ASCLETIS") ANNOUNCES TODAY THAT ITS NEW DRUG APPLICATION (NDA) FOR DENIFANSTAT (ASC40), A FIRST-IN-CLASS, ONCE-DAILY ORAL SMALL MOLECULE FATTY ACID SYNTHASE (FASN) INHIBITOR FOR THE TREATMENT OF MODERATE-TO-SEVERE ACNE VULGARIS, HAS BEEN ACCEPTED BY THE CHINA NATIONAL MEDICAL PRODUCTS ADMINISTRATION (NMPA).

ASCLETIS ANNOUNCES CHINA NATIONAL MEDICAL PRODUCTS ADMINISTRATION ACCEPTANCE OF NEW DRUG APPLICATION FOR DENIFANSTAT (ASC40), A FIRST-IN-CLASS FASN INHIBITOR FOR ACNE TREATMENT

- USING ASCLET I S' PROPRIETARY U LTRA- L ONG- A CTING P LATFORM TECHNOLOGY, CO-FORMULATION OF ASC36, A ONCE-MONTHLY SUBCUTANEOUSLY ADMINISTERED AMYLIN RECEPTOR PEPTIDE AGONIST AND ASC35, A ONCE-MONTHLY SUBCUTANEOUSLY ADMINISTERED GLP-1R/GIPR DUAL PEPTIDE AGONIST, DEMONSTRATED A COMPARABLE PHARMACOKINETIC (PK) PROFILE TO ASC36 AND ASC35 DOSED ALONE IN HEAD-TO-HEAD NON-HUMAN PRIMATE STUDIES. - ASC36 MONOTHERAPY DEMONSTRATED APPROXIMATELY 32 % GREATER RELATIVE BODY WEIGHT REDUCTION COMPARED TO ELORALINTIDE MONOTHERAPY IN A HEAD-TO-HEAD DIET-INDUCED OBESE (DIO) RAT STUDY, WHILE ASC35 MONOTHERAPY DEMONSTRATED APPROXIMATELY 71% GREATER RELATIVE BODY WEIGHT REDUCTION COMPARED TO TIRZEPATIDE MONOTHERAPY IN A HEAD-TO-HEAD DIO MOUSE STUDY.

ASCLETIS ANNOUNCES CO-FORMULATION OF ASC36, ONCE-MONTHLY NEXT-GENERATION AMYLIN RECEPTOR AGONIST AND ASC35, ONCE-MONTHLY NEXT-GENERATION GLP-1R/GIPR DUAL AGONIST FOR CLINICAL DEVELOPMENT

HAMILTON, BERMUDA , NOV. 5, 2025 /PRNEWSWIRE/ -- ARDMORE SHIPPING CORPORATION (NYSE: ASC) ("ARDMORE", THE "COMPANY" OR "WE") TODAY ANNOUNCED RESULTS FOR THE THREE AND NINE MONTHS ENDED SEPTEMBER 30, 2025. HIGHLIGHTS AND RECENT ACTIVITY REPORTED ADJUSTED EARNINGS OF $12.6 MILLION AND NET INCOME ATTRIBUTABLE TO COMMON STOCKHOLDERS OF $12.1 MILLION FOR THE THREE MONTHS ENDED SEPTEMBER 30, 2025, OR $0.31 ADJUSTED EARNINGS PER BASIC AND DILUTED SHARE, COMPARED TO ADJUSTED EARNINGS AND NET INCOME ATTRIBUTABLE TO COMMON STOCKHOLDERS OF $23.3 MILLION, OR $0.55 ADJUSTED EARNINGS PER BASIC AND DILUTED SHARE FOR THE THREE MONTHS ENDED SEPTEMBER 30, 2024.

ARDMORE SHIPPING CORPORATION ANNOUNCES FINANCIAL RESULTS FOR THE THREE AND NINE MONTHS ENDED SEPTEMBER 30, 2025

-POSITIVE DATA FROM PHASE IB STUDY OF ASC30 ORAL TABLET DEMONSTRATED UP TO 6.5% PLACEBO-ADJUSTED MEAN BODY WEIGHT REDUCTION; SAFE AND WELL TOLERATED WITH ONLY MILD-TO-MODERATE GASTROINTESTINAL (GI) ADVERSE EVENTS (AES) ACROSS ALL MULTIPLE ASCENDING DOSE (MAD) COHORTS. -PHASE IB STUDY DATA OF ASC30 SUBCUTANEOUS (SQ) INJECTION SHOWED THAT OBSERVED HALF-LIFE REACHED 46 DAYS FOR THE TREATMENT FORMULATION (INJECTION A) AND 75 DAYS FOR THE MAINTENANCE FORMULATION (INJECTION B).

ASCLETIS PRESENTS FULL ANALYSIS OF PHASE IB STUDY OF ASC30 ORAL TABLET, PHASE IB STUDY OF ASC30 INJECTION, AND PRECLINICAL STUDY OF COMBINATION OF ASC31 AND ASC47 AT OBESITYWEEK 2025

-IN HEAD-TO-HEAD NON-HUMAN PRIMATE (NHP) STUDIES, AVERAGE OBSERVED HALF-LIFE OF ASC36 WAS APPROXIMATELY 15 DAYS, 3 -FOLD LONGER THAN PETRELINTIDE, WHICH SUPPORTS ONCE-MONTHLY SUBCUTANEOUS (SQ) DOSING IN HUMANS. -ASC36 DEMONSTRATED APPROXIMATELY 91 % GREATER RELATIVE BODY WEIGHT REDUCTION COMPARED TO PETRELINTIDE IN A HEAD-TO-HEAD DIET-INDUCED OBESE ( DIO ) RAT STUDY.

ASCLETIS SELECTS A BEST-IN-CLASS ONCE-MONTHLY SUBCUTANEOUSLY ADMINISTERED AMYLIN RECEPTOR AGONIST, ASC36, FOR CLINICAL DEVELOPMENT

DOWNERS GROVE, ILL.--(BUSINESS WIRE)--DULY HEALTH AND CARE, THROUGH ITS CHICAGOLAND MEDICAL GROUP, DUPAGE MEDICAL GROUP, LTD., HAS ANNOUNCED THE ACQUISITION OF A MINORITY OWNERSHIP INTEREST IN VALLEY AMBULATORY SURGERY CENTER (VALLEY ASC) IN PARTNERSHIP WITH SURGERY PARTNERS. THIS COLLABORATION STRENGTHENS DULY'S COMMITMENT TO EXPANDING ACCESS TO HIGH-QUALITY, AFFORDABLE OUTPATIENT SURGICAL CARE ACROSS THE CHICAGOLAND AREA. VALLEY ASC, LOCATED IN ST. CHARLES, ILLINOIS, IS A RESPECTED, MULTISPEC.

DULY HEALTH AND CARE EXPANDS OUTPATIENT SURGERY ACCESS THROUGH MINORITY SHARE ACQUISITION OF VALLEY ASC IN PARTNERSHIP WITH SURGERY PARTNERS

-MULTIPLE POSTERS BEING PRESENTED ON ASCLETIS' SMALL MOLECULE AND PEPTIDE OBESITY PROGRAMS -FULL ANALYSIS OF 28-DAY MULTIPLE ASCENDING DOSE STUDY OF ORAL GLP-1R SMALL MOLECULE AGONIST ASC30 AS A LATE-BREAKING POSTER AS WELL AS ASC30 ONCE-MONTHLY TREATMENT FORMULATION AND ONCE-QUARTERLY MAINTENANCE FORMULATION HONG KONG , OCT. 27, 2025 /PRNEWSWIRE/ -- ASCLETIS PHARMA INC. (HKEX: 1672, "ASCLETIS") ANNOUNCES MULTIPLE POSTER PRESENTATIONS OF ITS OBESITY ASSETS INCLUDING ASC30, AND COMBINATION OF ASC31 AND ASC47 AT OBESITYWEEK2025 IN ATLANTA, GEORGIA. PRESENTATION DETAILS: ABSTRACT TITLE:A FULL ANALYSIS OF 28-DAY MAD STUDY OF ORAL GLP-1R BIASED SMALL MOLECULE AGONIST ASC30 FOR OBESITY PRESENTATION TIME: NOVEMBER 4, 2025, 7:30 P.M.

ASCLETIS TO PRESENT STUDY RESULTS OF ASC30 ORAL TABLET, ASC30 INJECTION, AND COMBINATION OF ASC31 AND ASC47 AT OBESITYWEEK 2025

HAMILTON, BERMUDA , OCT. 22, 2025 /PRNEWSWIRE/ -- ARDMORE SHIPPING CORPORATION (NYSE: ASC) ("ARDMORE" OR THE "COMPANY") TODAY ANNOUNCED THAT THE COMPANY PLANS TO ANNOUNCE ITS THIRD QUARTER EARNINGS BEFORE THE MARKET OPENS WEDNESDAY, NOVEMBER 5, 2025 AND WILL HOST A CONFERENCE CALL LATER IN THE DAY AT 10:00 A.M. EASTERN TIME.

ARDMORE SHIPPING ANNOUNCES THIRD QUARTER 2025 CONFERENCE CALL AND WEBCAST

- DENIFANSTAT (ASC40) MET ALL PRIMARY, KEY SECONDARY AND SECONDARY EFFICACY ENDPOINTS (ITT ANALYSIS) AND SIGNIFICANTLY IMPROVED MODERATE-TO-SEVERE ACNE VULGARIS COMPARED WITH PLACEBO IN A PHASE III RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, MULTICENTER CLINICAL TRIAL. HONG KONG , OCT. 14, 2025 /PRNEWSWIRE/ --ASCLETIS PHARMA INC. (HKEX: 1672, "ASCLETIS") ANNOUNCES TODAY THAT IT RECENTLY COMPLETED THE PRE-NEW DRUG APPLICATION (NDA) CONSULTATION WITH CHINA NATIONAL MEDICAL PRODUCTS ADMINISTRATION (NMPA) FOR DENIFANSTAT (ASC40) FOR THE TREATMENT OF MODERATE-TO-SEVERE ACNE VULGARISAND PLANS TO SUBMIT AN NDA SOON.

Ardmore Shipping Corporation

ASC

Price

Financial Reports

No items found.

Press Releases

Ardmore Shipping Corporation

ASC.css-1jgtvd5{-webkit-user-select:none;-moz-user-select:none;-ms-user-select:none;user-select:none;width:1em;height:1em;overflow:hidden;display:inline-block;text-align:center;-webkit-flex-shrink:0;-ms-flex-negative:0;flex-shrink:0;font-size:1.5rem;}

Price

Financial Reports

No items found.

Press Releases

ASC